Online inquiry

IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13755MR)

This product GTTS-WQ13755MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ANGPTL3 gene. The antibody can be applied in Hypertriglyceridemia&Homozygous familial hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014495.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27329
UniProt ID Q9Y5C1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13755MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2275MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ7918MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ3337MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ12144MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ4542MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ14025MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ9957MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KBSA301
GTTS-WQ14304MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-7221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW